复宏汉霖拟向Alvogen Korea授出独家许可,供其于韩国于领域内商业化汉斯状®

格隆汇
25 Apr

格隆汇4月25日丨复宏汉霖(02696.HK)宣布,公司于2025年4月25日与Alvogen Korea订立一份许可协议,据此,公司向Alvogen Korea授出独家许可,供其于韩国于领域内商业化汉斯状®(斯鲁利单抗注射液)(“许可产品”或“汉斯状®”)。汉斯状®为公司自主开发的创新型抗PD-1单抗,其于中国大陆境内(不包括中国港澳台地区,下同)已获批上市的适应症包括联合化疗一线治疗鳞状非小...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10